| Literature DB >> 27716088 |
Vicki Flenady1,2, Aleena M Wojcieszek3,4, Ingvild Fjeldheim5, Ingrid K Friberg5, Victoria Nankabirwa6,7, Jagrati V Jani5,7, Sonja Myhre5, Philippa Middleton4,8, Caroline Crowther8,9, David Ellwood4,10, David Tudehope3, Robert Pattinson11, Jacqueline Ho12, Jiji Matthews13, Aurora Bermudez Ortega14, Mahima Venkateswaran5,7, Doris Chou15, Lale Say15, Garret Mehl15, J Frederik Frøen4,5,7.
Abstract
BACKGROUND: Electronic health registries - eRegistries - can systematically collect relevant information at the point of care for reproductive, maternal, newborn and child health (RMNCH). However, a suite of process and outcome indicators is needed for RMNCH to monitor care and to ensure comparability between settings. Here we report on the assessment of current global indicators and the development of a suite of indicators for the WHO Essential Interventions for use at various levels of health care systems nationally and globally.Entities:
Keywords: Intervention coverage; Maternal health; Newborn health; Outcome indicators; Performance indicators; Perinatal health; Process indicators; Registries; ehealth
Mesh:
Year: 2016 PMID: 27716088 PMCID: PMC5045645 DOI: 10.1186/s12884-016-1049-y
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Major sources for identifying existing indicators
| WHO and UNAIDS indicators | Other indicators |
|---|---|
| • The World Health Statistics 2011 Indicator Code Book [ | • The official list of MDG Indicators (mdgs.un.org) |
Website links correct as at July 2015, we acknowledge links may be updated in future
Current status of use of global indicators for the 45 included WHO Essential Interventions
| Intervention | Population data | Facility data | ||||||
|---|---|---|---|---|---|---|---|---|
| Screening process indicator | Screening outcome indicator | COVERAGE/Management process indicator | Management outcome indicator | Availability of supplies | Staff ever trained | Ever performed at this facility | ||
| Preconception/ Periconception and Pregnancy | Folic acid supplementation or fortification | NA | NA | – | – | 5 of 7i | 4 of 7 | 3 of 7 |
| Family planninga | – | 22 % | 31 % | 4 % | 5 of 7 | 4 of 7 | 3 of 7 | |
| Prevention and management of STIs and HIV | – | – | – | – | 1 of 7 | 2 of 7 | 2 of 7 | |
| Safe abortion services | – | – | 26 % | – | 4 of 7 | 2 of 7 | 4 of 7 | |
| Post-abortion care | – | – | – | – | 2 of 7 | 2 of 7 | 2 of7 | |
| Antenatal care visit (1+) (contact) | NA | NA | 84 % | – | NA | NA | NA | |
| Antenatal care visit (4+) (contact) | NA | NA | 57 % | – | NA | NA | NA | |
| Essential packageb | NA | NA | – | – | 4 of 7 | 4 of 7 | 3 of 7 | |
| Iron and folic acid supplementationc | NA | NA | 26 % | – | 4 of 7 | 2 of 7 | 3 of 7 | |
| Tetanus toxoid vaccinationd | NA | NA | 81 % | – | 4 of 7 | 0 of 7 | 3 of 7 | |
| Prevention of malaria with prophylactic antimalarials | NA | NA | 27 % | – | 4 of 7 | 4 of 7 | 4 of 7 | |
| Prevention of malaria with ITN | NA | NA | 37 % | – | ||||
| Smoking cessation during pregnancy | – | – | – | – | 0 of 7 | 0 of 7 | 0 of 7 | |
| Detection and management of syphilise | 44 % | 2 % | 37 % | – | 5 of 7 | 5 of 7 | 5 of 7 | |
| Detection and management of HIV (including PMTCT)f | – | 3 % | 67 % |
| 6 of 7 | 4 of 7 | 6 of 7 | |
| Calcium supplementation for deficient women in pregnancy | – | – | – | – | 1 of 7 | 0 of 7 | 0 of 7 | |
| Aspirin for pre-eclampsia prevention | – | – | 1 of 7 | 0 of 7 | 0 of 7 | |||
| Antihypertensive drugs for hypertension in pregnancy | – | – | 3 of 7 | 0 of 7 | 1 of 7 | |||
| Anticonvulsants (i.e., MgSO4) | – | – | – | – | 7 of 7 | 2 of 7 | 3 of 7 | |
| External cephalic version | – | – | – | – | 0 of 7 | 0 of 7 | 0 of 7 | |
| Induction of labor after pPRoM | – | – | – | – | 0 of 7 | 0 of 7 | 1 of 7 | |
| Antibiotics for pPRoM | – | – | – | – | 6 of 7 | 0 of 7 | 3 of 7 | |
| Antenatal corticosteroids | – | – | – | – | 4 of 7 | 0 of 7 | 1 of 7 | |
| Childbirth and postpartum care | Skilled attendant at birth (contact) | NA | NA | 66 % | – | NA | NA | NA |
| Facility delivery (contact) | NA | NA | 63 % | – | NA | NA | NA | |
| Social support during childbirth | NA | NA | – | – | 0 of 7 | 0 of 7 | 0 of 7 | |
| Prophylactic antibiotics for cesarean section | – | – | – | – | 5 of 7 | 1 of 7 | 3 of 7 | |
| Cesarean section | – | – | 10 % | – | 3 of 7 | 2 of 7 | 4 of 7 | |
| Uterotonics for prevention of hemorrhage | NA | NA | – | – | 8 of 8 | 5 of 8 | 6 of 8 | |
| Active management of the 3rd stage of labor | NA | NA | – | – | 8 of 8 | 5 of 8 | 4 of 8 | |
| Induction at ≥ 41 weeks of gestation | – | – | – | – | 0 of 7 | 0 of 7 | 1 of 7 | |
| Uterotonics for treatment of hemorrhage | – | – | – | – | 8 of 8 | 2 of 8 | 5 of 8 | |
| Manual removal of the placenta | – | – | – | – | 4 of 7 | 2 of 7 | 3 of 7 | |
|
| – | 3 % | 67 % | 17 % | 6 of 7 | 4 of 7 | 6 of 7 | |
|
| – | 22 % | 31 % | 4.00 % | 5 of 7 | 4 of 7 | 3 of 7 | |
|
| – | 3 % | 67 % | 17 % | 6 of 7 | 4 of 7 | 6 of 7 | |
| Treat maternal anemiag | – | 40 % | – | – | 0 of 7 | 0 of 7 | 0 of 7 | |
| Detect and manage postpartum sepsis | – | – | – | – | 0 of 7 | 1 of 7 | 1 of 7 | |
| Newborns and small and ill babies | Immediate thermal care | – | – | – | – | 4 of 7 | 3 of 7 | 2 of 7 |
| Promotion and support for early Initiation of breastfeeding | NA | NA | 50 % | – | 1 of 7 | 4 of 7 | 3 of 7 | |
| Promotion and provision of hygienic cord and skin care | NA | NA | – | – | 1 of 7 | 2 of 7 | 2 of 7 | |
| Neonatal resuscitation | – | – | – | – | 6 of 7 | 3 of 7 | 6 of 7 | |
| Newborn Immunizationh | NA | NA | 91 %/37 % | – | 2 of 7 | 0 of 7 | 1 of 7 | |
| Presumptive antibiotic therapy for newborns at risk of bacterial infection | – | – | – | – | 2 of 7 | 1 of 7 | 2 of 7 | |
| Case management of neonatal sepsis, meningitis, and pneumonia | – | – | – | – | 2 of 7 | 1 of 7 | 2 of 7 | |
|
| – | 3 % | 67 % | 17 % | 6 of 7 | 4 of 7 | 6 of 7 | |
| Kangaroo mother care for preterm and for <2000 g babies | – | – | – | – | 1 of 7 | 1 of 7 | 1 of 7 | |
| Extra support for feeding the small and preterm baby | – | – | – | – | 0 of 7 | 0 of 7 | 1 of 7 | |
| Prophylactic and therapeutic use of surfactant | – | – | – | – | 0 of 7 | 0 of 7 | 1 of 7 | |
| Continuous positive airway pressure (CPAP) for RDS | – | – | – | – | 0 of 7 | 0 of 7 | 1 of 7 | |
| Management of newborns with Jaundice | – | – | – | – | 1 of 7 | 0 of 7 | 1 of 7 | |
aScreening outcome indicator is unmet need for family planning; coverage indicator is contraceptive prevalence rate; management outcome is total fertility rate
bShould include measurement of blood pressure, anaemia, and identification of pre-eclampsia
cindicator is percent of women taking 90+ days of iron supplementation, available from household surveys
dSource: data.unicef.org; defined as percent of neonates protected at birth from tetanus infection
eSource: WHO Global observatory; 56 countries with Process indicator, 62 with outcome, 31 with coverage able to be estimated
fScreening outcome is modelled results of HIV prevalence, available from aidsinfoonline.org/devinfo/libraries/aspx/Home.aspx; coverage indicator is percent of population in need with HIV managed, available from data.unicef.org; Management indicator is Paediatric transmission rate, available from data.unicef.org
gAnaemia prevalence in any woman of reproductive age, available from household surveys
hSource: data.unicef.org; BCG and Hepatitis B birth dose vaccinations
iThe number of survey instruments which cover this topic out of all the survey instruments which could have covered this topic. Thus 7 survey instruments were identified for all topics except for haemorrhage for which 8 survey instruments were identified
αDuplicate indicators
Fig. 1Countries represented by expert panel across scoring rounds (N = 31)
Fig. 2Evaluation for prophylactic antimalarial for preventing malaria in pregnancy treatment outcome indicator #3: Malaria-specific stillbirth rate (per 100,000 births) (n = 4)
Fig. 3Correlation between indicator prevalence, statistical power and population size. Not all available indicators should be used equally when evaluating different levels of a health system. The selection of evaluation indicators should vary based on whether there is adequate power to measure a significant change and whether the outcome is modifiable by that level of the health system, a different set of indicators is appropriate for quality improvement at clinics than for national planning purposes. The figure indicates that a typical clinic (e.g. a facility with 200 births per year) only has adequate power to identify large differences in relatively frequent events, such as process indicators for interventions needed universally (i.e. SBA, immediate breastfeeding). Districts (10,000 births annually) have the ability to monitor relatively rare process indicators (management of maternal haemorrhage) as well as relatively common impacts (i.e. stillbirths) while populations the size of a typical country (e.g. 500,000 births annually) are needed to monitor rare outcomes (i.e. cause specific maternal mortality ratios or early neonatal mortality rates). All levels of the health system should be aware of the full range of indicators, but should only be evaluated on those which are appropriate at that specific level